Study of TSG-6 expression and mechanism of action in thyroid-related eye diseases

The role and mechanism of TSG-6/TGF-ß/Smad pathway in inhibiting abnormal proliferation of orbital fibroblasts in thyroid-related eye diseases

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300069111

Enrollment

Unknown

Registered

2023-03-07

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid-associated ophthalmopathy

Interventions

thyroid-associated ophthalmopathy group:N/A

Control group:N/A

Eligibility

Sex/Gender

All

Age

20 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients with thyroid-related eye disease between the ages of 20 and 55 who do not respond to glucocorticoids and other second-line therapy and require surgery

Exclusion criteria

Exclusion criteria: (1) Unstable thyroid function, (2) history of ocular trauma and surgery, (3) history of orbital radiotherapy and chemotherapy, (4) local infection or inflammation of the orbit, (4) local infection or inflammation of the orbit

Design outcomes

Primary

Measure	Time frame
TSG-6 low expression;	—

Secondary

Measure	Time frame
IL-6 high expression;TNF-a high expression;	—

Countries

China

Contacts

Public ContactYuxin Xu

Second Affiliated Hospital of Anhui Medical University

xuyuxin1168@sina.com13866752297

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026